Goldman Sachs tips ResMed share price to race higher

The ResMed Inc. (ASX:RMD) share price could race higher after Goldman Sachs lifted its price target…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price was one of the best performers on the ASX 200 last week.

During the period the sleep treatment-focused medical device company's shares recorded a 7% weekly gain.

Why did ResMed's shares race higher?

The driver of this impressive gain was the release of a very strong quarterly update.

That update saw ResMed post first quarter revenue of US$681.1 million, up 16.1% on the prior corresponding period.

Pleasingly, thanks to further improvements in its margins, net operating profit increased at an even quicker rate of 19%. This led to the company posting diluted earnings per share of 93 U.S. cents.

Both its revenue and earnings smashed the market's expectations, leading to investors scrambling to pick up shares.

Is it too late to invest?

I don't believe it is too late to invest. I still see a lot of value in its shares for investors focused on making a buy and hold investment.

This view is echoed by analysts at Goldman Sachs. A note out of the investment bank reveals that they have retained their buy rating and lifted the price target on its shares to $23.20. This price target implies potential upside of more than 10% over the next 12 months.

Goldman was impressed with ResMed's performance in the first quarter, particularly from its masks business. It said: "The greater share of today's +8% beat is driven by masks (+19% in each of US and RoW is the strongest performance since disclosed separately), and 1Q20 is the 9th consecutive quarter of double-digit EBIT growth (+22%)."

And while the broker expects this growth to moderate, it still sees solid growth ahead.

"Whilst these rates are unlikely sustainable, we expect masks to continue to deliver low-teens growth (GSe: +13%), driven by effective portfolio management and successful re-supply programs," it added.

The broker also spoke positively about its valuation. Pointing out that although its shares have hit an all-time high, they are still trading below the healthcare peer group of Cochlear Limited (ASX: COH), CSL Limited (ASX: CSL), and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).

Overall, I think Goldman makes some great points and suspect its shares may be heading higher again today.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Opinions

Too high? These 2 ASX shares might be due for a correction

These popular blue chips are looking dicey to me.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in June

These stocks could be best buys this month according to the broker.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Why Clarity, Coronado Global, Iperionx, and Lynas shares are roaring higher today

These shares are having a strong session on Thursday. Why are investors buying them?

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
Opinions

The ASX 200 is approaching its all-time high. Here's why I'm not buying shares

I'm not seeing what the broader market is.

Read more »